Clarivate Epidemiology's coverage of NK/T-cell lymphoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of NK/T-cell lymphoma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, EU5 and Japan, and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are forecasted across the developed world.
Clarivate Epidemiology's NK/T-cell lymphoma forecast will answer the following questions:
In developing countries, what impact will economic growth and development have on the number of people diagnosed with NK/T-cell lymphoma per year?
How will improvements in survival change the number of people diagnosed with NK/T-cell lymphoma per year?
Of all people diagnosed with NK/T-cell lymphoma, how many in each country across the world are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NK/T-cell lymphoma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
Clarivate Epidemiology provides at least ten years of forecast data for the following NK/T-cell lymphoma patient populations:
Incidence of NK/T-cell lymphoma per 100,000 People of All Ages in 2021 and 2031t
Relative Sizes of the Contributing Factors to the Trend in Diagnosed Incident Cases of NK/T-cell lymphoma over the Next Ten Years
Epidemiology Data
Methods
Diagnosed Incident Cases
Diagnosed Prevalent Cases
Reference Materials
Literature Review
Studies Included in the Analysis of NK/T-cell lymphoma
Studies Excluded from the Analysis of NK/T-cell lymphoma
Risk/Protective Factors
Risk/Protective Factors for NK/T-cell lymphoma
Bibliography
Abbreviations
Glossary
Pramilesh Tekchand Suryawanshi
Pramilesh Suryawanshi, M.P.H., is an associate epidemiologist at Clarivate. Previously, Mr. Suryawanshi worked with Pathfinder International in Lepra, the Netherlands Leprosy Relief Foundation, and the National Health Mission. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai, where he worked on several public health projects, including the assessment of social health insurance schemes. He holds a bachelor’s degree in the Indian system of medicine (Ayurveda) from Rajiv Gandhi University of Health Sciences in Karnataka.
Narendra Parihar
Narendra Parihar, M.P.H., is a principal epidemiologist at Clarivate. His areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. A former dentist, he earned his M.P.H. from the Tata Institute of Social Sciences in Mumbai.